Latest Intelligence

Published within

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: Enbrel inflames profits

Wyeth has reported positive second quarter earnings, thanks in part to strong demand for the arthritis treatment Enbrel. With its launch in Japan already boosting sales, even with a drop in the drug's hard-sell marketing post-Vioxx, it is expected to remain well-positioned to carry the fight to Centocor's competing Remicade.

Published By Datamonitor
21 Jul 2005
CommentWire
CommentWire

Wyeth: Effexor XR is deemed effective

Wyeth has released the findings of the study, which pooled together results of eight double-blind studies and compared Effexor XR to a leading serotonin selective re-uptake inhibitor. Although the drug's sales should be high it could suffer at the hands of strong competition from Lilly's duloxetine.<BR />

Published By Datamonitor
13 Dec 2002
CommentWire
CommentWire

Wyeth: Effexor unsuitable for depressed children

Wyeth [WYE] has warned that its antidepressant Effexor (venlafaxine) is not effective for treating depression in children and teenagers, raising further concerns over the safety of prescribing antidepressants to children. However, due to the drug's ongoing success and growth it is unlikely this latest warning will have a significant effect on Effexor's sales.

Published By Datamonitor
08 Sep 2003
CommentWire
CommentWire

Wyeth: diversity key to growth

Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />

Published By Datamonitor
05 Jun 2003
CommentWire
CommentWire

Wyeth: breast cancer prospects receive a blow

Wyeth has discontinued a phase III trial of temsirolimus plus letrozole in metastatic post-menopausal hormone-receptor positive breast cancer. This is a significant blow for the company due to the loss of earnings potential in the congested but lucrative breast cancer market. However, temsirolimus remains under development for a number of other tumors, and so hope for the drug candidate remains.

Published By Datamonitor
23 Mar 2006
CommentWire
CommentWire

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor
09 Jan 2009
CommentWire
CommentWire

Wyeth: a question of consolidation

Revenues at Wyeth have climbed despite declining sales of key products such as Premarin and Prevnar. Litigation expenses continue to impact the bottom line, but a cash injection resulting from the merger of Immunex and Amgen has improved the company's financial situation. There are signs the company could be ripe for consolidation once more.

Published By Datamonitor
30 Jan 2003
CommentWire
CommentWire

Wyeth/MedImmune: the end of the road for FluMist venture

Following poor first-year performance, Wyeth [WYE] and MedImmune [MEDI] have announced the dissolution of their FluMist partnership. If MedImmune is to achieve success with this product alone, it may need to rethink its premium pricing strategy.

Published By Datamonitor
28 Apr 2004
CommentWire
CommentWire

Wyeth/MedImmune: second generation vaccine

Wyeth [WYE] and MedImmune's [MEDI] FluMist failed to secure indications for use in key target groups for influenza vaccine in the US. Recently released results suggest that their second generation product may enable the two companies to capitalize on more conventional influenza vaccine sectors.

Published By Datamonitor
15 Oct 2003
CommentWire
CommentWire

Wyeth Ayerst/Celltech: Mylotarg brings new hope

Published By Datamonitor
04 Dec 2000

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

No help is available.